ACADIA Pharmaceuticals (ACAD) Given Media Sentiment Score of 0.16
Media coverage about ACADIA Pharmaceuticals (NASDAQ:ACAD) has trended somewhat positive on Friday, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ACADIA Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.2394253534016 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news articles that may have impacted Accern’s analysis:
- Hot Stock of the Day – ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – The Investor Guide (wallstreetnews24.com)
- Alexion (ALXN) Reports Interim Results for Soliris Study (finance.yahoo.com)
- Stocks Gaining Momentum on SMA and Performance Valuation: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – NASDAQ Times (nasdaqtimes.com)
- ACADIA Pharmaceuticals Inc. (ACAD) 10.69% away from 20 SMA – Voice Of Analysts (analystsbuzz.com)
- ACADIA Pharmaceuticals Inc. (ACAD) is at $37.08 per share and DexCom, Inc. (DXCM) is listed at $73.13 – Stocks Gallery (stocksgallery.com)
Shares of ACADIA Pharmaceuticals (NASDAQ ACAD) opened at 36.37 on Friday. ACADIA Pharmaceuticals has a 1-year low of $20.68 and a 1-year high of $40.83. The company’s market capitalization is $4.45 billion. The stock has a 50 day moving average price of $32.72 and a 200 day moving average price of $31.61.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.17. The business had revenue of $30.50 million during the quarter, compared to analyst estimates of $20.02 million. ACADIA Pharmaceuticals had a negative return on equity of 62.08% and a negative net margin of 485.14%. The business’s revenue was up 30400.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.63) earnings per share. On average, equities analysts anticipate that ACADIA Pharmaceuticals will post ($2.55) EPS for the current fiscal year.
ACAD has been the subject of several research analyst reports. Rodman & Renshaw reiterated a “buy” rating and set a $60.00 target price on shares of ACADIA Pharmaceuticals in a research report on Monday, May 22nd. ValuEngine upgraded ACADIA Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. BidaskClub upgraded ACADIA Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, June 21st. Zacks Investment Research upgraded ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and set a $31.00 target price for the company in a research report on Tuesday, July 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of ACADIA Pharmaceuticals in a research report on Wednesday, August 9th. Six analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $43.23.
In other news, EVP Glenn Baity sold 38,097 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $30.00, for a total value of $1,142,910.00. Following the completion of the sale, the executive vice president now directly owns 109,253 shares in the company, valued at $3,277,590. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 80,829 shares of company stock valued at $2,623,850 over the last 90 days. Company insiders own 22.25% of the company’s stock.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).
Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.